A randomized trial of nicotine enemas for active ulcerative colitis.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Nicotine enemas cause fewer AEs and were used as supplemental treatment for active UC.

Who Took Part

The study group was 104 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Patients continued their oral therapy, if any, for UC: 68 patients were taking mesalamine, 15 patients were taking prednisolone, and 12 patients were taking thiopurines during the study.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some patients received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

AEs and salivary cotinine levels were monitored throughout the study.

What Was Measured

The subject headings attached to it are Colitis, Ulcerative, Enema, Mesalamine, Nicotine, Prednisolone and Sigmoidoscopy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 104 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.